Title
A novel real-time RT-PCR assay for influenza C tested in Peruvian children
Date Issued
01 November 2017
Access level
open access
Resource Type
journal article
Author(s)
Howard L.M.
Johnson M.
Pekosz A.
Griffin M.R.
Edwards K.M.
Grijalva C.G.
Williams J.V.
Publisher(s)
Elsevier B.V.
Abstract
Background Influenza C virus (ICV) is associated with acute respiratory illness. Yet ICV remains under recognized, with most previous studies using only culture to identify cases. Objectives To develop a sensitive and specific real-time RT-PCR assay for ICV that allows for rapid and accurate detection in a clinical or research setting. Study design Multiple ICV sequences obtained from GenBank were analyzed, including 141 hemagglutinin-esterase (HE), 106 matrix (M), and 97 nucleoprotein (NP) sequences. Primers and probes were designed based on conserved regions. Multiple primer-probe sets were tested against multiple ICV strains. Results The ICV M and NP genes offered the most conserved sequence regions. Primers and probes based on newer sequence data offered enhanced detection of ICV, especially for low titer specimens. An NP-targeted assay yielded the best performance and was capable of detecting 10–100 RNA copies per reaction. The NP assay detected multiple clinical isolates of ICV collected in a field epidemiology study conducted in Peru. Conclusions We report a new real-time RT-PCR assay for ICV with high sensitivity and specificity.
Start page
12
End page
16
Volume
96
Language
English
OCDE Knowledge area
Tecnología médica de laboratorio (análisis de muestras, tecnologías para el diagnóstico)
Tecnología para la identificación y funcionamiento del ADN, proteínas y enzimas y como influencian la enfermedad)
Subjects
Scopus EID
2-s2.0-85029320190
PubMed ID
Source
Journal of Clinical Virology
ISSN of the container
1386-6532
Sponsor(s)
JVW serves on the Scientific Advisory Board of Quidel and an Independent Data Monitoring Committee for GlaxoSmithKline. MRG has received grant funding from MedImmune. KME has received research funding and serves on a Data Safety and Monitoring Board for Novartis. CGG has served as consultant for Pfizer and Merck. CFL is an advisor to Takeda Vaccines Division. All other authors have no potential competing interests to report.
Financial support: JVW was supported by NIH AI-085062. This work was partially supported by the Vanderbilt University CTSA grant UL1 RR024975 from National Institutes of Health, an investigator initiated research grant from Pfizer IIR WS1898786(0887X1-4492), http://www.pfizer.com , and grant 02832-9 from the Thrasher Research Fund ( www.thrasherresearch.org/default.aspx ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Sources of information:
Directorio de Producción Científica
Scopus